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BACKGROUND: In recent years, several groups have reported dominant inheritance of obesity conferred by missense, nonsense
and frameshift mutations in the melanocortin 4 receptor gene (MC4R). Hence, MC4R is involved in the most common
monogenic form of human obesity described so far.
OBJECTIVES: In this context, we screened a Spanish population, composed of obese subjects and normal weight controls, for
mutations in the MC4-R by single-strand conformational polymorphism (SSCP).
SUBJECTS AND METHODS: Overall 313 individuals, 159 obese subjects (body mass index: BMI: 37.6 kg/m2, 95% CI: 36.7–
38.5 kg/m2) and 154 normal weight control subjects (BMI: 22.3 kg/m2, 95% CI: 22.0–22.6 kg/m2) were screened for MC4-R
mutations.
RESULTS: We detected a novel nonsense mutation at codon 16 of the MC4-R in an obese female (BMI: 30.0 kg/m2) and a
previously described missense mutation (Val-253-Ile) located within the sixth trans-membrane domain of the MC4-R in a normal
weight individual (BMI: 19.0 kg/m2). The polymorphism Val-103-Ile was detected in one obese individual, while four subjects
(two cases and two controls) with the polymorphism Ile-251-Leu were found.
CONCLUSIONS: We have identified a novel nonsense mutation (Trp-16-Stop) that, based on previously described frameshift
and nonsense mutations, most likely results in dominantly inherited obesity. Within this Spanish population, the frequency of
the Ile-251-Leu polymorphism of the MC4R was similar in obese and control subjects (about 1.3%), while the polymorphism Val-
103-Ile was only detected in an obese individual (0.6%).
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Introduction
Dominant inheritance of obesity conferred by missense,
nonsense and frameshift mutations in the melanocortin 4
receptor gene (MC4R) has been extensively reported in many
populations including French, English, German, American
and Italian individuals.1–12 Several mutations of the MC4R,
mainly one nonsense (Tyr-35-Stop) and three frameshift
mutations (732-733insGATT, 631-634delCTCT, 47-48insG)
can be considered loss-of-function mutations and are
associated with dominant inheritance of obesity. Functional
studies showed that many of the missense muations also lead
to a loss of function of the MC4R.5,6,8,13 However, other
mutations (ie Thr-11-Ser, Arg-18-Cys) and two polymorph-
isms (Val-103-Ile, Ile-251-Leu) did not modify the function
of the MC4R in vitro.5,7 It has been estimated that 2–4% of
extremely obese individuals harbor functionally relevant
MC4R mutations.14 In this Spanish study, we assessed
mutation rates in 159 obese cases and 154 normal weight
controls. The repeated comparison of mutation rates be-
tween obese and control study groups is useful for assessing
the functional implication of MC4R mutations in the
etiology of obesity.
Materials and methods
The study population comprised 313 Spanish subjects, aged
20–60 y and it is based on a case–control design. Cases
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(BMI>30 kg/m2) were recruited at the Endocrinology Depart-
ment at the Navarra Hospital and controls (BMIo25 kg/m2)
were ascertained by the Occupational Health Department at
the same hospital, between January 1999 and June 2000.
Exclusion criteria were current hormonal treatment or
obesity secondary to endocrine disorder or serious inter-
current illness. Subjects with type II diabetes, not receiving
glucose-lowering agents, were eligible as cases (9%). In total,
159 obese patients (BMI mean: 37.6 kg/m2; 95% CI: 36.7–
38.5 kg/m2) and 154 normal weight subjects (BMI mean:
22.3 kg/m2; 95% CI: 22.0–22.6 kg/m2) were selected. Con-
trols were healthy subjects having a BMIo25 kg/m2 with no
apparent disease and blood pressure below 120/90. Re-
sponses rates were acceptable (65% for cases and 75% for
controls) and the interviews were all conducted in a medical
enviroment. The study was approved by the Ethics Commit-
tee of the University of Navarra and all subjects provided
written informed consent for participation. The reported
investigation has been carried out according to the principles
of the Declaration of Helsinki II.
Anthropometric measurements were made by standard
procedures and fat mass was measured by bioelectrical
impedance. Following a 12 h fast, venous blood samples
were obtained and serum glucose and lipids were measured
by enzymatic methods. Serum insulin was measured by
radioimmunoassay (TK/N1, Diagnostic Product Corporation,
Los Angeles-California, USA) and plasma leptin by enzyme-
immune assay (EIA-1863, DRG Diagnostics, Germany) as
described elsewhere.15 Blood samples were taken for the
extraction and characterization of genomic DNA from
leukocytes. Single strand Conformational polymorphism
(SSCP) analysis for mutations in the MC4-R was performed
as previously reported.3 By sequencing of PCR products
showing an aberrant SSCP pattern, we identified several
heterozygous carriers of mutations and polymorphisms
(Figure 1b). The Trp-16-Stop mutation was additionally
verified by digestion of the MC4R PCR-fragment 1;3 whereby
the 16-Trp allele was digested with BspLI (Fermentas) and the
16-Stop allele remained uncut.
Results
We identified four different variants: a novel nonsense (Trp-
16-Stop) mutation, a previously described missense muta-
tion (Val-253-Ile), as well as two known polymorphisms Val-
103-Ile and Ile-251-Leu (Table 1). The clinical characteristics
of the MC4R mutation carriers are indicated in Table 2. The
Val-103-Ile polymorphism was detected in one (BMI: 35.4 kg/
m2) out of the 159 obese individuals, while we identified two
controls and two obese subjects with the Ile-251-Leu
polymorphism.
The obese female heterozygous for the Trp-16-Stop muta-
tion (II2 in Figure 1a) reported early onset of obesity at age 8.
She additionally reported having continuously restricted her
energy intake in the sense of being on a constant diet. Her
maximum weight was 100 kg (BMI 34.6 kg/m2, at age 30 y).
Recently, an abdominal lipectomy was performed for
cosmetic reasons. She inherited the mutation from her
mother (I2 in Figure 1a). Her mother reported adolescenct
onset of obesity. She has also been continuously attempting
to restrict her energy intake, her maximum weight was 80 kg
at age 30 y (max BMI: 30.5 kg/m).
Hormone measurements were performed in the index
proband. The corticotropic and thyrotropic axe was normal
(ACTH¼8.5 ng/l [0.1–46]; cortisol 08.00 h 20 mg/dl [5–25];
cortisol after dexamethasone (Nugent test): 0.6 mg/dl; T4
free¼1.1 ng/dl; TSH¼0.72 mIU/l [0.35–4.0]). The mother of
the index proband, who also carries the nonsense mutation,
was not avalilable for this determination.
Discussion
Here we report for the first time the nonsense mutation Trp-
16-Stop in the MC4R. The female index patient is not
characterized by any readily detectable phenotypic abnorm-
ality other than early onset obesity. She inherited the
mutation from her mother, who is also a heterozyous carrier
and who has a history of obesity. This novel nonsense
MUTATED: C  A  C C  T  C T   G   A A A C 
His Leu Stop
WILD:  C  A  C   C   T  C   T   G   G A A C 
His  Leu Trp Asp
Codon:   14 15    16    17 
       I     1 2
       II 1 2 3 4 5 
       III 1 2 
Phenotypic data  
I1 I2 II1 III2 
Age in years 58    9 
BMI in kg/m2
III1II5 
 II4  II3 II2
1324 29  34 323753
30    15 2422 23  22 303028
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Figure 1 (a) Pedigree of the obese index patient harboring the Trp-16-Stop
mutation in the MC4R. (b) MC4R partial sequencing and deduced amino-acid
sequences of the patient II-2. The arrow indicates the position of the G/A
substitution. The base substituted is underlined. Grey symbols correspond to
obese subjects, a middle line represents carriers of the Trp-16-Stop of the
MC4R, an arrow indicates the index patient.
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mutation at codon 16 of the MC4R should lead to a receptor
that is truncated at the N-terminal extracellular domain. It
resembles the nonsense mutation Tyr-35-Stop, which was
also associated with obesity.3 It is readily evident that the
gene products of these two nonsense mutations cannot
function based on previous pharmacological characteriza-
tions of other nonsense and frameshift mutations.1,4
In a normal weight control subject, we detected a
previously described missense mutation (Val-253-Ile) that is
located within the sixth trans-membrane domain of the
MC4R.4,7 Presently, few missense variants of MC4R have
been described in normal weight individuals.4,5
The Ile-251-Leu polymorphism was detected in two
normal weight and two obese subjects, a similar result was
reported by Vaisse et al7 and Hinney et al3 in a French and a
German study, respectively. However, Farooqi et al4 found
more carriers of this polymorphism among obese indivi-
duals. Functional analyses revealed that this missense
variant is indistinguishable from the wild-type receptor,7 so
that this variant presumably represents a polymorphism,
which is not functionally relevant. The polymorphism Val-
103-Ile has been reported in many individuals of different
ethnic origins with frequencies ranging from 0.5 (8) to 5.1
(3) percent. In a British study group, Gotoda et al16 described
similar allele frequencies in obese and normal weight
subjects. Most of the reports did not find association with
obesity.3–5,7,16. This corresponds with normal signaling
properties of the 103-Ile receptor variant in functional
studies.5,13 In our study, we only found one obese subject
carrier of the Val-103-Ile polymorphism.
In conclusion: (a) a novel nonsense mutation in the MC4R,
most likely underlying dominantly inherited obesity, was
identified in an obese female; (b) within the Spanish
population, the frequency of the Ile-251-Leu polymorphism
of the MC4R was similar in obese and normal weight subjects
(about 1.3%), while the polymorphism Val-103-Ile was only
detected in an obese individual (0.6%).
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Table 1 MC4R mutation screening in obese and normal weight individuals
Base change Effect on amino-acid sequence Control (n=154) Obese (n=159)
G-48-A Trp-16-Stopa 0 1
G-757-A Val-253-Ile 1 0
A-307-G Val-103-Ile 0 1
A-751-C Ile-251-Leu 2 2
Both groups were screened by SSCP.
aNovel mutation in the MCR-4 sequence.
Table 2 Phenotypic characteristics of MC4R mutation carriers in comparison with the complete screened study groups
Variable Control Obese W16X V253I V103I I251L I251L
(n=154) (n=159) Obese Control Obese Control 1 Control 2 Obese 1 Obese 2
Age (y) 39 [37–40] 42 [41–44] 32 26 39 42 47 48 30
Sex (F/M) 113/41 139/20 F F F F F F F
Current weight 61 [59–63] 96 [93–98] 85 55 80 52 51 93 77
BMI (kg/m2) 22.3 [22.0–22.4] 37.6 [36.7–38.5] 30.0 19.0 35.4 20.8 24.3 39.9 30.1
WHR 0.80 [0.79–0.80] 0.89 [0.88–0.90] 0.96 0.84 0.92 0.74 0.75 0.92 0.83
Max weight (kg) 65 [64–67] 99 [97–102] 94 58 80 55 56 93 82
% fat mass 28 [27–28] 43 [42–45] 43 27 41 26 32 39 38
SBP (mmHg) 111 [109–113] 138 [135–141] 125 100 140 110 100 140 120
DBP (mmHg) 69 [68–70] 88 [86–90] 85 60 90 60 70 90 80
Glucose(mM/l) 5.1 [5.0–5.3] 5.6 [5.4–5.9] 6.3 4.8 4.6 5.8 4.5 5.5 4.8
Insulin (pM/l) 54 [49–59] 149 [126–171] 480 54 66 67 35 132 138
TC (mM/l) 5.1 [4.9–5.2] 5.4 [5.2–5.5] 6.8 6.0 4.5 4.8 5.3 4.3 5.1
TG (mM/l) 0.7 [0.7–0.8] 1.3 [1.2–1.4] 3.1 0.6 1.4 0.6 0.7 1.1 1.4
Leptin (ng/ml) 7.9 [6.7–9.1] 34.4 [29.5–39.3] 28.2 4.7 27.0 5.4 5.8 34.8 18.4
Values are mean [95% CI] when indicated. Max: maximum; BPS, BPD: systolic and diastolic blood pressure; TC: total cholesterol; TG: triglycerides.
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